Conclusions Neither paroxetine nor high dose imipramine showed efficacy for major depression in adolescents, and there was an increase in harms with both drugs.
Our RIAT analysis of Study 329 showed that neither paroxetine nor high dose imipramine was effective in the treatment of major depression in adolescents, and there was a clinically significant increase in harms with both drugs.
We identified one study, however, in which the trialists intentionally chose to withhold data on a statistically significant increase in harm associated with the trial intervention.
The results from this study differ from previous Australian studies that found no change in harm associated with the alcopops tax.
However, it has become apparent that existing reduced harm tobacco products, such as brands formerly marketed as "light," present no obvious reduction in harm compared with regular, full flavor products [Hecht et al., 2005].
The less cash available due to welfare quarantining may have reduced the frequency and stake size of bets in community card games leading to a reduction in harm associated with gambling.
It pointed to a steep rise in self harm, with Childline reporting a 41% increase in 2013 and a 33% rise in the number of children reporting suicidal thoughts in one year.
Eighty-four (87%) of 97 reports described medication provision issues that resulted in patient harm, with n = 13 (13%) of those causing moderate harm or worse.
Fifty-eight (94%) of 62 reports involving non-provision or availability of therapeutic adjuncts resulted in patient harm, with n = 4, (7%) of those describing moderate harm or worse.
Overall, 259 AEs (55.7%) resulted in temporary harm with a complete recovery expected within 12 months, while 89 AEs (19.1%) caused long-term or permanent impairment or resulted in permanent institutional or nursing care.
